Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Summary

Cardiol Therapeutics filed a US$150 million preliminary base shelf prospectus with the Ontario Securities Commission for potential future capital raises. The company is a late-stage biopharmaceutical firm developing anti-inflammatory and anti-fibrotic therapies for heart disease.